433 related articles for article (PubMed ID: 27119269)
1. Roles of collagen Q in MuSK antibody-positive myasthenia gravis.
Ohno K; Otsuka K; Ito M
Chem Biol Interact; 2016 Nov; 259(Pt B):266-270. PubMed ID: 27119269
[TBL] [Abstract][Full Text] [Related]
2. Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.
Otsuka K; Ito M; Ohkawara B; Masuda A; Kawakami Y; Sahashi K; Nishida H; Mabuchi N; Takano A; Engel AG; Ohno K
Sci Rep; 2015 Sep; 5():13928. PubMed ID: 26355076
[TBL] [Abstract][Full Text] [Related]
3. [Anti-MuSK antibodies in myasthenia gravis block binding of collagen Q to MuSK].
Ohno K
Rinsho Shinkeigaku; 2012; 52(11):1306-8. PubMed ID: 23196600
[TBL] [Abstract][Full Text] [Related]
4. Anti-MuSK autoantibodies block binding of collagen Q to MuSK.
Kawakami Y; Ito M; Hirayama M; Sahashi K; Ohkawara B; Masuda A; Nishida H; Mabuchi N; Engel AG; Ohno K
Neurology; 2011 Nov; 77(20):1819-26. PubMed ID: 22013178
[TBL] [Abstract][Full Text] [Related]
5. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
[TBL] [Abstract][Full Text] [Related]
6. The collagen ColQ binds to LRP4 and regulates the activation of the Muscle-Specific Kinase-LRP4 receptor complex by agrin at the neuromuscular junction.
Uyen Dao TM; Barbeau S; Messéant J; Della-Gaspera B; Bouceba T; Semprez F; Legay C; Dobbertin A
J Biol Chem; 2023 Aug; 299(8):104962. PubMed ID: 37356721
[TBL] [Abstract][Full Text] [Related]
7. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
Koneczny I; Cossins J; Waters P; Beeson D; Vincent A
PLoS One; 2013; 8(11):e80695. PubMed ID: 24244707
[TBL] [Abstract][Full Text] [Related]
8. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies to agrin in myasthenia gravis patients.
Zhang B; Shen C; Bealmear B; Ragheb S; Xiong WC; Lewis RA; Lisak RP; Mei L
PLoS One; 2014; 9(3):e91816. PubMed ID: 24632822
[TBL] [Abstract][Full Text] [Related]
10. Collagen Q is a key player for developing rational therapy for congenital myasthenia and for dissecting the mechanisms of anti-MuSK myasthenia gravis.
Ohno K; Ito M; Kawakami Y; Ohtsuka K
J Mol Neurosci; 2014 Jul; 53(3):359-61. PubMed ID: 24234034
[TBL] [Abstract][Full Text] [Related]
11. Developmental consequences of the ColQ/MuSK interactions.
Karmouch J; Dobbertin A; Sigoillot S; Legay C
Chem Biol Interact; 2013 Mar; 203(1):287-91. PubMed ID: 23089045
[TBL] [Abstract][Full Text] [Related]
12. Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.
Takamori M
Front Mol Neurosci; 2020; 13():86. PubMed ID: 32547365
[TBL] [Abstract][Full Text] [Related]
13. [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].
Ohta R; Motomura M
Rinsho Byori; 2014 Mar; 62(3):255-60. PubMed ID: 24800501
[TBL] [Abstract][Full Text] [Related]
14. Myasthenia gravis experimentally induced with muscle-specific kinase.
Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
[TBL] [Abstract][Full Text] [Related]
15. Collagen Q--a potential target for autoantibodies in myasthenia gravis.
Zoltowska Katarzyna M; Belaya K; Leite M; Patrick W; Vincent A; Beeson D
J Neurol Sci; 2015 Jan; 348(1-2):241-4. PubMed ID: 25577314
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.
Zhang B; Tzartos JS; Belimezi M; Ragheb S; Bealmear B; Lewis RA; Xiong WC; Lisak RP; Tzartos SJ; Mei L
Arch Neurol; 2012 Apr; 69(4):445-51. PubMed ID: 22158716
[TBL] [Abstract][Full Text] [Related]
17. [Autoantibodies in myasthenia gravis].
Motomura M; Narita Masuda T
Brain Nerve; 2013 Apr; 65(4):433-9. PubMed ID: 23568991
[TBL] [Abstract][Full Text] [Related]
18. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
19. [Genetic defects and disorders at the neuromuscular junction].
Ohno K
Brain Nerve; 2011 Jul; 63(7):669-78. PubMed ID: 21747136
[TBL] [Abstract][Full Text] [Related]
20. ColQ controls postsynaptic differentiation at the neuromuscular junction.
Sigoillot SM; Bourgeois F; Lambergeon M; Strochlic L; Legay C
J Neurosci; 2010 Jan; 30(1):13-23. PubMed ID: 20053883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
